Similar articles

• ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.

  Curtiss FR. Curtiss FR. J Manag Care Pharm. 2003 Mar-Apr;9(2):178-81. doi: 10.18553/jmcp.2003.9.2.178. J Manag Care Pharm. 2003. PMID: 14613350 Free PMC article. No abstract available.
• Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.

  Hiligsmann M, Ben Sedrine W, Reginster JY. Hiligsmann M, et al. J Bone Miner Res. 2013 Apr;28(4):807-15. doi: 10.1002/jbmr.1819. J Bone Miner Res. 2013. PMID: 23165656
• Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.

  Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B. Kanis JA, et al. Osteoporos Int. 2005 Jan;16(1):15-25. doi: 10.1007/s00198-004-1688-0. Epub 2004 Jul 24. Osteoporos Int. 2005. PMID: 15672210 Clinical Trial.
• Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.

  Cranney A, Adachi JD. Cranney A, et al. Drug Saf. 2005;28(8):721-30. doi: 10.2165/00002018-200528080-00006. Drug Saf. 2005. PMID: 16048357 Review.
• A comparison between bisphosphonates and other treatments for osteoporosis.

  Le Goff B, Guillot P, Glémarec J, Berthelot JM, Maugars Y. Le Goff B, et al. Curr Pharm Des. 2010;16(27):3037-44. doi: 10.2174/138161210793563563. Curr Pharm Des. 2010. PMID: 20722614 Review.